Jazz Pharmaceuticals (JAZZ) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.

Do analysts prefer JAZZ or RPRX?

Jazz Pharmaceuticals currently has a consensus price target of $177.00, indicating a potential upside of 46.06%. Royalty Pharma has a consensus price target of $41.67, indicating a potential upside of 35.50%. Given Jazz Pharmaceuticals' higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more volatility and risk, JAZZ or RPRX?

Jazz Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.

Which has better earnings & valuation, JAZZ or RPRX?

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Royalty Pharma is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$3.83B	1.91	$414.83M	$7.10	17.07
Royalty Pharma	$2.36B	7.69	$1.13B	$1.93	15.93

Does the MarketBeat Community prefer JAZZ or RPRX?

Jazz Pharmaceuticals received 801 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 80.76% of users gave Jazz Pharmaceuticals an outperform vote while only 67.92% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Jazz Pharmaceuticals	Outperform Votes 1125 80.76%	Underperform Votes 268 19.24%
Royalty Pharma	Outperform Votes 324 67.92%	Underperform Votes 153 32.08%

Is JAZZ or RPRX more profitable?

Royalty Pharma has a net margin of 50.53% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	11.60%	29.30%	9.72%
Royalty Pharma	50.53%	24.65%	14.44%

Do insiders and institutionals hold more shares of JAZZ or RPRX?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 18.9% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media refer more to JAZZ or RPRX?

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Royalty Pharma. MarketBeat recorded 13 mentions for Jazz Pharmaceuticals and 6 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.16 beat Jazz Pharmaceuticals' score of 0.91 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Jazz Pharmaceuticals beats Royalty Pharma on 11 of the 19 factors compared between the two stocks.